ImageONE (2667) · FactReframed
Sales Concentration in 東京医療化学
First written in FY2018. 6 of 7 entries say "Reframed", first in FY2019. Latest entry: FY2024.
7entries
8years
0from disclosures
How it moved
Same theme, other companies
Disclosure of Major Customers and Customer Sales MixA theme 16 companies write about · 12 as a headwind · 0 as a tailwind
ImageONE moved to the "Worse" side of this theme in 2019.
The whole theme swung hardest in 2024: 2 of 12 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.Full recordFilings, disclosures and news, newest first
- FY2024ReframedAnnual report
「Sales to ＲＢソーラーアーク合同会社 and ＲＢソーラーディタ合同会社 for the current fiscal year are omitted because each represented less than 10% of total sales.」
The 2 renewable energy-related companies disclosed as major customers in the previous fiscal year each accounted for less than 10% of total sales in the current fiscal year, changing the concentration of major customers. - FY2023ReframedAnnual report
「ＲＢソーラーアーク合同会社 686,092 22.3; ＲＢソーラーディタ合同会社 620,000 20.1」
The composition of major customers changed, with 2 companies in the renewable energy sector accounting for 22.3% and 20.1% of total sales, respectively. - FY2022ReframedAnnual report
「トータル・プランニング 368,740 10.75」
Sales to トータル・プランニング of ¥368.74 million were listed as sales to a major customer for the current fiscal year, representing 10.75% of total sales. The composition of major customers changed from previous fiscal years. - FY2021ReframedAnnual report
「494,740 20.31 486,086 19.95 262,458 10.77」
In the current fiscal year, sales to 3 customers whose identities were not disclosed due to confidentiality obligations accounted for 20.31%, 19.95% and 10.77%, respectively, changing the concentration of sales from the composition of major customers in the previous fiscal year. - FY2020ReframedAnnual report
「588,000 29.7 543,425 27.4」
In the current fiscal year, sales to 2 customers whose identities were not disclosed due to confidentiality obligations accounted for ¥588 million and 29.7%, and ¥543 million and 27.4%, respectively. The concentration of sales shifted from the composition of major customers in the previous fiscal year. - FY2019ReframedAnnual report
「岩手県 Medical Bureau — — 283,400 15.1」
Sales to 東京医療化学株式会社, which accounted for 23.7% in the previous fiscal year, fell below 10% in the current fiscal year. Meanwhile, sales to the 岩手県 Medical Bureau accounted for 15.1%, and sales for which the counterparty was not disclosed due to contractual confidentiality obligations accounted for 22.9%, changing the composition of major customers. - FY2018First statedAnnual report
「東京医療化学株式会社 392,288 23.7」
For the current fiscal year, sales to 東京医療化学株式会社 were ¥392.288 million, representing 23.7% of total sales.